Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation

Journal of Immunology

Volumn 174, Issue 1, 2005, Pages 164-173

  Sugiyama, Hideaki ^a,b   Gyulai, Rolland ^a,c   Toichi, Eiko ^a,d   Garaczi, Edina ^a,c   Shimada, Shinji ^b   Stevens, Seth R ^a,e   McCormick, Thomas S ^a   Cooper, Kevin D ^a,e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c UNIVERSITY OF SZEGED   (Hungary)

^d KYOTO UNIVERSITY   (Japan)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CHEMOKINE RECEPTOR CXCR3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR;

ARTICLE; BLOOD; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; EPIDERMIS CELL; HUMAN; HUMAN CELL; INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN CELL; T LYMPHOCYTE; TARGET ORGAN; TH1 CELL; TH2 CELL;

EID: 10844222790     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.1.164     Document Type: Article

References (52)

1. Maloy, K. J., and F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816.
2. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387.
3. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969.
4. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287.
5. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160:1212.
6. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431.
7. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295.
8. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
9. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162:5317.
10. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164:183.
11. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303.
12. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193:1285.
13. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295.
14. + T cells with regulatory properties from human blood. J. Exp. Med. 193:1303.
15. high regulatory cells in human peripheral blood. J. Immunol. 167:1245.
16. Becker, K. G., R. M. Simon, J. E. Bailey-Wilson, B. Freidlin, W. E. Biddison, H. F. McFarland, and J. M. Trent. 1998. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl. Acad. Sci. USA 95:9979.
17. Nair, R. P., T. Henseler, S. Jenisch, P. Stuart, C. K. Bichakjian, W. Lenk, E. Westphal, S. W. Guo, E. Christophers, J. J. Voorhees, et al. 1997. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum. Mol. Genet. 6:1349.
18. Weinstein, G. D., and P. Frost. 1968. Abnormal cell proliferation in psoriasis. J. Invest. Dermatol. 50:254.
19. Baadsgaard, O., E. Hansen, L. Chan, P. Tong, G. L. Wantzin, J. J. Voorhees, D. A. Fox, and K. D. Cooper. 1988. Lesional psoriasis T cell cultures reflect the in situ subset distribution and demonstrate autoreactivity. J. Invest. Dermatol. 90:544.
20. Baadsgaard, O., G. Fisher, J. J. Voorhees, and K. D. Cooper. 1990. The role of the immune system in the pathogenesis of psoriasis. J. Invest. Dermatol. 95:32S.
21. + perivascular dendritic cells. J. Invest. Dermatol. 96:333.
22. Nestle, F. O., L. A. Turka, and B. J. Nickoloff. 1994. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94:202.
23. Levantine, A., and J. Brostoff. 1975. Immunological responses of patients with psoriasis and the effect of treatment with methotrexate. Br. J. Dermatol. 93:659.
24. Brostoff, S. 1995. The development and use of T cell receptor peptide vaccines. Adv. Exp. Med. Biol. 383:249.
25. Chang, J. C., L. R. Smith, K. J. Froning, H. H. Kurland, B. J. Schwabe, K. K. Blumeyer, M. A. Karasek, D. I. Wilkinson, E. M. Farber, D. J. Carlo, et al. 1997. Persistence of T-cell clones in psoriatic lesions. Arch. Dermatol. 133:703.
26. Wong, R. L., C. M. Winslow, and K. D. Cooper. 1993. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol. Today 14:69.
27. + subsets. J. Invest. Dermatol. 111:1072.
28. Ferenczi, K., L. Burack, M. Pope, J. G. Krueger, and L. M. Austin. 2000. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14:63.
29. de Jong, R., A. C. Bezemer, T. P. Zomerdijk, T. van de Pouw-Kraan, T. H. Ottenhoff, and P. H. Nibbering. 1996. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26:2067.
30. Krueger, J. G., I. B. Walters, M. Miyazawa, P. Gilleaudeau, J. Hakimi, S. Light, A. Sherr, and A. B. Gottlieb. 2000. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43:448.
31. Mrowietz, U., K. Zhu, and E. Christophers. 2000. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch. Dermatol. 136:675.
32. Ellis, C. N., and G. G. Krueger. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345:248.
33. + cells. J. Immunol. 168:4462.
34. Krueger, G. G. 2002. Selective targeting of T cell subsets: focus on alefacept: a remittive therapy for psoriasis. Expert. Opin. Biol. Ther. 2:431.
35. Wrone-Smith, T., and B. J. Nickoloff. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98:1878.
36. Prinz, J. C., B. Gross, S. Vollmer, P. Trommler, I. Strobel, M. Meurer, and G. Plewig. 1994. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur. J. Immunol. 24:593.
37. Bata-Csorgo, Z., C. Hammerberg, J. J. Voorhees, and K. D. Cooper. 1995. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture: cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95:317.
38. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971.
39. + regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 199:1285.
40. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057.
41. + T regulatory cells. Nat. Immunol. 4:337.
42. + regulatory T cells. Nat. Immunol. 4:330.
43. Fuhlbrigge, R. C., J. D. Kieffer, D. Armerding, and T. S. Kupper. 1997. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 389:978.
44. Davison, S. C., A. Ballsdon, M. H. Allen, and J. N. Barker. 2001. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp. Dermatol. 10:280.
45. + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 31:1247.
46. Cooper, K. D. 1992. Skin-infiltrating lymphocytes in normal and disordered skin: activation signals and functional roles in psoriasis and mycosis fungoides-type cutaneous T cell lymphoma. J. Dermatol. 19:731.
47. Vollmer, S., A. Menssen, P. Trommler, D. Schendel, and J. C. Prinz. 1994. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 24:2377.
48. Prens, E. P., T. van Joost, J. P. Hegmans, K. t Hooft-Benne, O. E. Ysselmuiden, and R. Benner. 1995. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J. Am. Acad. Dermatol. 33:947.
49. 5 integrin regulate keratinocyte cell cycling: a mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J. Clin. Invest. 101:1509.
50. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198:235.
51. + regulatory T cells in vivo. J. Exp. Med. 198:249.
52. + suppressor-inducer T cells. J. Immunol. 145:2854.